ASH: Another 'off-the-shelf' cell therapy leader shows durability issues, raising renewed concerns about emerging field

Kyle Blankenship

The next generation of cell therapies have focused in large part on the development of allogeneic — better known as “off-the-shelf — drugs that can cut manufacturing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

ASH: Another 'off-the-shelf' cell therapy leader shows durability issues, raising renewed concerns about emerging field

Kyle Blankenship

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Pfizer CEO says opportunities with Trump ‘clearly outweigh’ the risks for pharma

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

FDA approves first drug to treat ultra-rare lipid storage disease

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

ASH: An­oth­er 'off-the-shelf' cell ther­a­py leader shows dura­bil­i­ty is­sues, rais­ing re­newed con­cerns about emerg­ing field

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

ASH: Another 'off-the-shelf' cell therapy leader shows durability issues, raising renewed concerns about emerging field